In part 3 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the heart complication and amputation risks on the greater population.

In part 4 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about insurance coverage of SGLT-2 drugs and the challenges for patients with heart and kidney issues.

In part 5 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about studies on the use of SGLT in other populations — people without diabetes, people with kidney disease, etc.

In part 6 of this Exclusive Interview, John Buse compares the Observe 4D study to other similar studies in a conversation with Diabetes in Control Publisher Steve Freed.

In part 7 of this Exclusive Interview, John Buse urges other medical professionals to weigh the risks and benefits of using SGLT in a conversation with Diabetes in Control Publisher Steve Freed.

In part 8, the conclusion of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the good and bad effects of using SGLT2 for patients who have type 1.

HbA1c used less frequently but results in more abnormal results, more diagnoses of prediabetes, diabetes

One of our brand managers in our office in Atlanta made the decision to move back to California and return to sales management. One of the things he left behind was a “standing desk.” There were four other people who wanted the desk, so we held a lottery. As you …

Researchers find increased risk in people with type 1 who have glucose levels greater than 8.0%.

More accurate genes to screen for type 1 diabetes in both newborns and adults identified.